

Resume of Hongda ZHD

Basic Information



School : College of Life Science and Health Engineering
Gender: Female
Date of Birth: 197409
Title: Associate Professor
Education: Ph.D of Biopharmaceutical engineering
Tutor: Doctor degree
E-mail: bszzhuhongda@yeah.net
Interest of research: Drug delivery system, Nanomedicine

Academic Background

From September 1992 to July 1996, Tongji Medical College, Bachelor's degree in Pharmacy;

From September 2005 to July 2007, Wuhan University, Master's degree of Pharmaceutics;

From September 2007 to March 2011, Huazhong University of Science and Technology, Ph.D of Biopharmaceutical engineering.

Oversea visiting

2016/03-2017/03, Visiting scholar, University of North Carolina at Chapel Hill, USA;

Enrollment Information

1. Enrollment Discipline: Master of Pharmacy, Master of Biology and Pharmaceuticals
2. Research direction: Drug delivery system, Nanomedicine, Oncology Pharmacology
3. Enrollment Year: 2023-2024

Representative Projects

1. The Ministry of Education's Humanities and Social Sciences Youth Project "Building a Countercyclical Macroprudential Regulatory Framework - Research Based on Basel III", China, Project leader.
2. Hubei University of Technology Green Industry Science and Technology Leadership Project "Independent Exploration Program, Exploring the Efficacy of Multiple Modulation Strategies of Immune Microenvironment in Triple-Negative Breast Cancer Immunotherapy by Nano Co-Delivery System", in progress, Project leader.
2. Chinese Society of Clinical Oncology (CSCO)-Hengrui Oncology Research Fund Project "Basic research on the application of new chemotherapy-immunotherapy combination regimen in triple-negative breast cancer based on the regulation of tumor immune microenvironment"(Y-HR2019-0325), in progress, Project leader.

3. National Natural Science Foundation of China (NSFC) Youth Program, “Construction of Reduction-Sensitive Triggered Nano-Pickering Breast Drug Delivery System and Targeting Hepatocellular Carcinoma” (NO: 81201197), Completed, Project leader.
4. National Natural Science Foundation of China (NSFC) “Construction of metal nanocyclic structure and graphene composite system and its application in surface-enhanced Raman scattering (SERS)” (NO:51371079), Completed, participated.
5. Natural Science Foundation of Hubei Province, “Reduction-responsive shell crosslinked polymer micelles for efficient encapsulation and target-controlled release of adriamycin” (NO: 2015CFB588), Completed, Project leader..

Representative Articles

- (1) Plant-derived extracellular vesicles as a promising anti-tumor approach: A comprehensive assessment of effectiveness, safety, and mechanisms, *Phytomedicine*, 2024, Pub Date : 2024-05-19.
- (2) Tumor-targeted self-assembled micelles reducing PD-L1 expression combined with ICIs to enhance chemo-immunotherapy of TNBC, *Chinese Chemical Letters*, 2023, 35: 108536
- (3) Tumor-targeted nano-adjuvants to synergize photomediated immunotherapy enhanced antitumor immunity, *VIEW*, 2023, 4: 20220067)
- (4) Co-delivery of minoxidil and tocopherol acetate ethosomes to reshape the hair Follicular Microenvironment and promote hair regeneration in androgenetic alopecia, *International Journal of Pharmaceutics*, 2023, 646: 123498
- (5) Selective Delivery of Tofacitinib Citrate to Hair Follicles Using Lipid-Coated Calcium Carbonate Nanocarrier Controls Chemotherapy-Induced Alopecia Areata, *Int. J. Mol. Sci.* 2023, 24, 8427.
- (6) Fabrication of oral nanovesicle in-situ gel based on Epigallocatechin gallate phospholipid complex: Application in dental anti-caries, *European Journal of Pharmacology*, 2021, 897: 173951
- (7) The clinical value of chemotherapy combined with capecitabine in triple-negative breast cancer-A meta-analysis. *Frontiers in Pharmacology*, 2021, 12: 771839.
- (8) Fabrication of oral nanovesicle in-situ gel based on Epigallocatechin gallate phospholipid complex: Application in dental anti-caries. *European Journal of Pharmacology*, 2021, 897, 173951.
- (9) Nanosuspension as an Efficient Carrier for Improved Ocular Permeation of Voriconazole. *Current Pharmaceutical Biotechnology*, 2021, 22(2): 245-253.
- (10) Remodeling the fibrotic tumor microenvironment of desmoplastic melanoma to facilitate vaccine immunotherapy, *Nanoscale*, 2020, 12: 3400-3410.